Investigation of adrenoceptor genes (β2 & β3) in women with polycystic ovary syndrome

Authors

  • Elahe Seyed Aboutorabi Reproductive Health Research Center of Vali-e-Asr, Vali-e-Asr Hospital 2, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Farideh Zafari Zangeneh Reproductive Health Research Center of Vali-e-Asr, Vali-e-Asr Hospital 2, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Masoumeh Masoumi Department of Biology, Faculty of Basic Sciences, Islamic Azad University, North Tehran Branch, Tehran, Iran.
Abstract:

Background: Genetic polymorphism is responsible for variations and individual differences. Polymorphism is a major factor of complex diseases with unknown etiology and cancer. Inconsistency in the symptoms of polycystic ovary syndrome (monthly disorder, hirsutism, obesity, diabetes, infertility) is one of the major pathological complications of this syndrome. The present study was conducted to evaluate the polymorphism gene β2 and β3 adrenergic receptors in women with polycystic ovary syndrome. Methods: This cross-sectional study was performed on 200 patients with polycystic ovary syndrome (PCOS) in Imam Khomeini Hospital, Vali-e-Asr Infertile Clinic in Tehran, Iran, from March 2016 to April 2017. Blood samples in two groups (study and control) were obtained for genomics approved by the DNA Company based on the gene bank. Polymerase chain reaction (PCR) samples were extracted and then the primer design was performed by using Primer Express software, version 3.0 (Applied Biosystems, Foster City, CA, USA) and confirmed by using of the primer blast tool at the NCBI site in terms of compliance with the beta 3 adrenergic receptor gene. Analysis of protein changes was performed by using CLUSTALW (https://www.genome.jp/tools-bin/clustalw). Polymorphism was investigated on codons 16, 27, 113 and 164 from the beta2 adrenoceptor gene and codon 64 of the beta3 adrenergic receptor gene. Results: The study of the codon beta2 of adrenoceptors showed that only codon 164 (Thr164Ile) polymorphism (44.4%) was significant (P<0/002) in study group. Homozygote and heterozygote ratios also show a significant difference between the study and control groups (P<0/004). Polymorphism exon 1 in codon 64 of beta3 adrenoceptor; which codes the amino acid tryptophan, indicates that the nucleotide T has changed to C. This finding confirms that mutagenic genotype can raise chance of getting to the polycystic ovary syndrome in women. OR: 2.546 (95% CI: 1.02-5.367) (P=0.012). Conclusion: These results show that polymorphisms of codon 164 (Thr164Ile) of beta2 receptor gene and beta3 adrenergic receptor gene polymorphism Thr164Ile (rs 4994) associate with polycystic ovary syndrome and the risk of PCOS are significantly increased in mutation genotype women.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Effect of aerobic training in women with polycystic ovary syndrome

Introduction: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder amongst women of reproductive age and is associated with various metabolic perturbations. Chronic low grade inflammation has been reported to participate in the pathogenesis of metabolic syndrome. In this study we examined the effects of 8 weeks aerobic training on serum C-reactive protein level and cardiometab...

full text

Mindfulness and Its Predictors in Women With Polycystic Ovary Syndrome

Background: Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in women of reproductive age which can cause many problems such as hyperandrogenic symptoms and fertility problems. Objective: The present study aimed to determine the relationship of mindfulness with hyperandrogenic symptoms and demographic and fertility factors in women with PCOS. Methods: This descriptive co...

full text

Investigation of genetic factors associated with polycystic ovary syndrome

Introduction: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders and causes 75% of infertility due to ovulation disorders in reproductive age. Women with PCOS have oligomenorrhea and hyperandrogenism that affect their quality of life and fertility at the same time. This syndrome has been one of the most controversial endocrine issues for many years. Research today su...

full text

Adiponectin in Women with Polycystic Ovary Syndrome

BACKGROUND Though adiponectin has been associated with insulin resistance and cardiovascular risk factors, the relationship between adiponectin and polycystic ovary syndrome (PCOS) remains controversial. The aim of this study was to compare adiponectin level in women with PCOS and without PCOS, and to investigate the relationship between adiponectin level and metabolic variables including insul...

full text

Sexuality in women with polycystic ovary syndrome.

OBJECTIVES This study aimed to compare sexual function and sexual response, attitude toward sexuality and relationships with sexual partners in women diagnosed with PCOS and healthy controls. MATERIAL AND METHODS The study included 73 women (aged 23-42 years) diagnosed with PCOS using the Rotterdam criteria and 45 healthy controls. All participants completed a questionnaire assessing socioepi...

full text

Dyslipidemia in women with polycystic ovary syndrome

Dyslipidemia is a very common metabolic abnormality in women with polycystic ovary syndrome (PCOS). Insulin resistance is a key pathophysiology of PCOS, thus dyslipidemia in women with PCOS may be consistent with those found in an insulin resistant state. In recent meta-analysis, triglycerides and low-density lipoprotein (LDL) cholesterol levels were 26 mg/dL and 12 mg/dL higher, and high-densi...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 76  issue 9

pages  588- 594

publication date 2018-12

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023